tiprankstipranks
Innate Pharma (IPHA)
NASDAQ:IPHA
US Market
IPHA
Innate Pharma
RESEARCH TOOLSreports

Innate Pharma (IPHA) Financial Statements

132 Followers

Innate Pharma Financial Overview

Innate Pharma's market cap is currently $130.56M. The company's EPS TTM is $-0.358; its P/E ratio is -1.23; Innate Pharma is scheduled to report earnings on March 26, 2026, and the estimated EPS forecast is $-0.33. See an overview of income statement, balance sheet, and cash flow financials.
Dec 25Dec 24Dec 23Dec 22Dec 21
Income Statement
Total Revenue€ 2.79M€ 12.62M€ 51.90M€ 57.67M€ 12.11M
Gross Profit€ 2.79M€ 12.62M€ 5.62M€ 6.01M€ -22.30M
Operating Income€ -53.42M€ -51.58M€ -12.67M€ -57.42M€ -47.83M
EBITDA€ -43.65M€ -46.91M€ -1.84M€ -12.28M€ -43.23M
Net Income€ -47.24M€ -49.47M€ -7.57M€ -58.10M€ -52.81M
Balance Sheet
Cash & Short-Term Investments€ 34.30M€ 80.77M€ 92.46M€ 101.48M€ 119.84M
Total Assets€ 62.69M€ 111.06M€ 175.19M€ 207.86M€ 267.50M
Total Debt€ 22.56M€ 31.00M€ 39.89M€ 42.25M€ 44.25M
Net Debt€ -5.52M€ -35.40M€ -30.71M€ -41.97M€ -59.51M
Total Liabilities€ 84.39M€ 102.22M€ 132.29M€ 153.71M€ 160.06M
Stockholders' Equity€ -21.69M€ 8.83M€ 51.90M€ 54.15M€ 107.44M
Cash Flow
Free Cash Flow€ -50.81M€ -7.29M€ -34.91M€ -20.28M€ -59.79M
Operating Cash Flow€ -50.67M€ -6.90M€ -32.56M€ -19.15M€ -58.46M
Investing Cash Flow€ 7.00M€ 9.20M€ 20.63M€ 1.88M€ -917.00K
Financing Cash Flow€ 5.83M€ -6.01M€ -1.97M€ -1.83M€ 26.82M
Currency in EUR

Innate Pharma Earnings and Revenue History

Income Statement >

Innate Pharma Debt to Assets

Balance Sheet >

Innate Pharma Cash Flow

Cash Flow >

Innate Pharma Forecast EPS vs Actual EPS

Earnings >